Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategy

11 Apr 2011

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chromatin Remodeling and Cancer
Share to Neurofibromatosis and Schwannoma Cases

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 21478905
DOI: 10.1038/onc.2011.80

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacologic reversal of epigenetic silencing of the anticancer protein BRM: a novel targeted treatment strategyPMID 21478905Read ↗

Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cellsSemantic proximity Read ↗

The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.Semantic proximity Read ↗

New approaches to molecular cancer therapeuticsSemantic proximity Read ↗

Death Receptor Pathway Activation and Increase of ROS Production by the Triple Epigenetic Inhibitor UVI5008Semantic proximity Read ↗

Epigenetic targeting of DNA damage response (DDR)-related mechanisms to overcome acquired cisplatin resistance of tumor cellsSemantic proximity Read ↗

Inhibiting RRM2 to enhance the anticancer activity of chemotherapySemantic proximity Read ↗

Novel inhibitors of the histone methyltransferase DOT1L show potent antileukemic activity in patient-derived xenograftsSemantic proximity Read ↗

Anti-cancer drug resistance: Understanding the mechanisms through the use of integrative genomics and functional RNA interferenceSemantic proximity Read ↗

Designing Effective Protein Lysine and Arginine Methyltransferase Inhibitors for Chemotherapeutic TargetingSemantic proximity Read ↗

Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51Semantic proximity Read ↗

Epigenetic drugs as immunomodulators for combination therapies in solid tumorsSemantic proximity Read ↗

[Epigenetics as a novel therapeutic target of cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.